# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Catalent (NYSE:CTLT) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.21 by 128...
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply con...
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts fo...
Stephens & Co. analyst Jacob Johnson reiterates Catalent (NYSE:CTLT) with a Equal-Weight and maintains $63.5 price target.
https://www.businesswire.com/news/home/20240402320363/en/
"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect ...